Involvement of membrane channels in autoimmune disorders

Current Pharmaceutical Design

Volumn 13, Issue 24, 2007, Pages 2456-2468

  Varga, Zoltán ^a   Hajdu, Péter ^a   Panyi, György ^a,b   Gáspár, Rezso ^a,b   Krasznai, Zoltán ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Autoantibody; Autoimmunity; Channelopathy; Fas signaling; Ion channel; T cell

Indexed keywords

3,4 DIAMINOPYRIDINE; AMPA RECEPTOR; AZATHIOPRINE; BERGAPTEN; CALCIUM ACTIVATED POTASSIUM CHANNEL; CALCIUM CHANNEL; CALCIUM CHANNEL L TYPE; CALCIUM ION; CD45RA ANTIGEN; CHEMOKINE RECEPTOR CCR7; CORTICOSTEROID; DILTIAZEM; FAS ANTIGEN; FAS LIGAND; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; IMMUNOGLOBULIN; ION CHANNEL; KALIOTOXIN; MYELIN BASIC PROTEIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; NICOTINIC RECEPTOR; NIFEDIPINE; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL KV1.2; POTASSIUM CHANNEL KV1.3; POTASSIUM CHANNEL KV1.5; SCORPION VENOM; SEA ANEMONE TOXIN; UNINDEXED DRUG; VERAPAMIL;

APOPTOSIS; AUTOIMMUNE DISEASE; CALCIUM SIGNALING; CELL MEMBRANE; CELL MEMBRANE POTENTIAL; CELL PROLIFERATION; CHRONIC GRAFT REJECTION; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG TARGETING; EARLY DIAGNOSIS; EATON LAMBERT SYNDROME; EFFECTOR CELL; ELECTROMYOGRAPHY; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOPATHOGENESIS; IMMUNOREGULATION; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; MYOKYMIA; NONHUMAN; PARANEOPLASTIC NEUROPATHY; PLASMAPHERESIS; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN FUNCTION; PSORIASIS; RASMUSSEN SYNDROME; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; ANIMAL; LYMPHOCYTE ACTIVATION; METABOLISM; PHYSIOLOGY; T LYMPHOCYTE;

ANIMALS; AUTOIMMUNE DISEASES; CELL MEMBRANE; HUMANS; ION CHANNELS; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES;

EID: 34548279933     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207781368576     Document Type: Review

References (150)

1. Ashcroft FM. Ion channels and disease. Academic Press, San Diego, CA. 2000.
2. Drachman DB, Angus CW, Adams RN, Michelson JD, Hoffman GJ. Myasthenic antibodies cross-ink acetylcholine receptors to accelerate degradation. N Engl J Med 1978; 298: 1116-22.
3. Lennon VA. Immunology of the acetylcholine receptor. Immunol Commun 1976; 5: 323-44.
4. Lang B, Newsom-Davis J, Prior C, Wray D. Antibodies to motor nerve terminals: An electrophysiological study of a human myasthenic syndrome transferred to mouse. J Physiol 1983; 344: 335-45.
5. Shillito P, Molenaar PC, Vincent A, Leys K, Zheng W, van den Berg RJ, et al. Acquired neuromyotonia: Evidence for autoantibodies directed against K+ channels of peripheral nerves. Ann Neurol 1995; 38: 714-22.
6. Lee EK, Maselli RA, Ellis WG, Agius MA. Morvan's fibrillary chorea: A paraneoplastic manifestation of thymoma. J Neurol Neurosurg Psychiatry 1998; 65: 857-62.
7. Gultekin SH, Rosenfeld MR, Voltz R, Eichen J, Posner JB, Dalmau J. Paraneoplastic limbic encephalitis: Neurological symptoms, immunological findings and tumour association in 50 patients. Brain 2000; 123 (Pt 7): 1481-94.
8. + channel in effector memory T cells as new target for MS. J Clin Invest 2003; 111: 1703-13.
9. Binah O. Cytotoxic lymphocytes and cardiac electrophysiology. J Mol Cell Cardiol 2002; 34: 1147-61.
10. Szabo I, Gulbins E, Apfel H, Zhang X, Barth P, Busch AE, et al. Tyrosine phosphorylation-dependent suppression of a voltage-gated K+ channel in T lymphocytes upon Fas stimulation. J Biol Chem 1996; 271: 20465-9.
11. Janeway CA, Travers P, Walport M, Shlomchik MJ. Immunobiology. New York Garland Publishing, New York, NY. 2001.
12. Bromley SK, Burack WR, Johnson KG, Somersalo K, Sims TN, Sumen C, et al. The immunological synapse. Annu Rev Immunol 2001; 19: 375-96
13. Monks CR, Freiberg BA, Kupfer H, Sciaky N, Kupfer A. Three-dimensional segregation of supramolecular activation clusters in T cells. Nature 1998; 395: 82-6.
14. van de Merwe PA. Formation and function of the immunological synapse. Curr Opin Immunol 2002; 14: 293-8.
15. Lewis RS. Calcium signaling mechanisms in T lymphocytes. Annu Rev Immunol 2001; 19: 497-521.
16. 2+-inhibited cation (MIC) channels. J Gen Physiol 2002; 119: 487-507.
17. Price P, Witt C, Allcock R, Sayer D, Garlepp M, Kok CC, et al. The genetic basis for the association of the 8.1 ancestral haplotype (A1, B8, DR3) with multiple immunopathological diseases. Immunol Rev 1999; 167: 257-74.
18. Roos J, DiGregorio PJ, Yeromin AV, Ohlsen K, Lioudyno M, Zhang S, et al. STIM1, an essential and conserved component of store-operated Ca2+ channel function. J Cell Biol 2005; 169: 435-45.
19. Rus H, Pardo CA, Hu L, Darrah E, Cudrici C, Niculescu T, et al. The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. Proc Nalt Acad Sci USA 2005; 102: 11094-9.
20. Russell JH, Ley TJ. Lymphocyte-mediated cytotoxicity. Annu Rev Immunol 2002; 20: 323-70.
21. Sabelko KA, Kelly KA, Nahm MH, Cross AH, Russell JH. Fas and Fas ligand enhance the pathogenesis of experimental allergic encephalomyelitis, but are not essential for immune privilege in the central nervous system. J Immunol 1997; 159: 3096-9.
22. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: Function, generation, and maintenance. Annu Rev Immunol 2004; 22: 745-63.
23. Salmaso C, Bagnasco M, Pesce G, Montagna P, Brizzolara R, Altrinetti V, et al. Regulation of apoptosis in endocrine autoimmunity: Insights from Hashimoto's thyroiditis and Graves' disease. Ann N Y Acad Sci 2002; 966: 496-501.
24. Schmitz A, Sankaranarayanan A, Azam P, Schmidt-Lassen K, Homerick D, Hansel W, et al. Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases. Mol Pharmacol 2005; 68: 1254-70.
25. Schon F, Drayson M, Thompson RA. Myasthenia gravis and elderly people. Age Ageing 1996; 25: 56-8.
26. Shilkrut M, Gealekman O, Rosen D, Berke G, Woodcock E, Binah O. Electrophysiologic perturbations and arrhythmogenic activity caused by activation of the Fas receptor in murine ventricular myocytes: Role of the inositol trisphosphate pathway. J Cardiovasc Electrophysiol 2001; 12: 185-95.
27. 2+ channels in human T cells: Pharmacology and molecular characterization of the major α pore-forming and auxiliary β-subunits. J Biol Chem 2004; 279: 19566-73.
28. Szabo I, Adams C, Gulbins E. Ion channels and membrane rafts in apoptosis. Pflugers Arch 2004; 448: 304-12.
29. Szabo I, Lepple-Wienhues A, Kaba KN, Zoratti M, Gulbins E, Lang F. Tyrosine kinase-dependent activation of a chloride channel in CD95-induced apoptosis in T lymphocytes. Proc Natl Acad Sci USA 1998; 95: 6169-74.
30. Takamori M, Maruta T, Komai K. Lambert-Eaton myasthenic syndrome as an autoimmune calcium-channelopathy. Neurosci Res 2000; 36: 183-91.
31. Tanaka M, Ito H, Adachi S, Akimoto H, Nishikawa T, Kasajima T, et al. Hypoxia induces apoptosis with enhanced expression of Fas antigen messenger RNA in cultured neonatal rat cardiomyocytes. Circ Res 1994; 75: 426-33.
32. Tomimitsu H, Arimura K, Nagado T, Watanabe O, Otsuka R, Kurono A, et al. Mechanism of action of voltage-gated K+ channel antibodies in acquired neuromyotonia. Ann Neurol 2004; 56: 440-44.
33. Toyka KV, Drachman DB, Griffin DE, Pestronk A, Winkelstein JA, Fishbeck KH, et al. Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice. N Engl J Med 1977; 296: 125-31.
34. Tsien RW, Lipscombe D, Madison D, Bley K, Fox A. Reflections on Ca(2+)-channel diversity, 1988-1994. Trends Neurosci 1995; 18: 52-4
35. Unwin N. Refined structure of the nicotinic acetylcholine receptor at 4A resolution. J Mol Biol 2005; 346: 967-89.
36. Valverde P, Kawai T, Taubman MA. Selective blockade of voltage-gated potassium channels reduces inflammatory bone resorption in experimental periodontal disease. J Bone Miner Res 2004; 19: 155-64.
37. Vennekamp J, Wulff H, Beeton C, Calabresi PA, Grissmer S, Hansel W, et al. Kv1.3-blocking 5-phenylalkoxypsoralens: A new class of immunomodulators. Mol Pharmacol 2004; 65: 1364-74.
38. Viglietta V, Kent SC, Orban T, Hafler DA. GAD65-reactive T cells are activated in patients with autoimmune type 1a diabetes. J Clin Invest 2002; 109: 895-903.
39. Vincent A. Understanding neuromyotonia. Muscle Nerve 2000; 23: 655-7
40. Vincent A. Unravelling the pathogenesis of myasthenia gravis. Nat Rev Immunol 2002; 2: 797-804.
41. Vincent A, Buckley C, Schott JM, Baker I, Dewar BK, Detert N, et al. Potassium channel antibody-associated encephalopathy: A potentially immunotherapy-responsive form of limbic encephalitis. Brain 2004; 127: 701-12.
42. Vincent A, Lang B, Kleopa KA. Autoimmune channelopathies and related neurological disorders. Neuron 2006; 52: 123-38.
43. Vincent A, McConville J, Farrugia ME, Bowen J, Plested P, Tang T, et al. Antibodies in myasthenia gravis and related disorders. Ann N Y Acad Sci 2003; 998: 324-35.
44. Vincent A, Newland C, Brueton L, Beeson D, Riemersma S, Huson SM, et al. Arthrogryposis multiplex congenita with maternal autoantibodies specific for a fetal antigen. Lancet 1995; 346: 24-5.
45. Vincent A, Palace J, Hilton-Jones D. Myasthenia gravis. Lancet 2001; 357: 2122-8.
46. Wiendl H, Bien CG, Bernasconi P, Fleckenstein B, Elger CE, Dichgans J, et al. GluR3 antibodies: Prevalence in focal epilepsy but no specificity for Rasmussen's encephalitis. Neurology 2001; 57: 1511-4
47. Wirtz PW, Willcox N, van der Slik AR, Lang B, Maddison P, Koeleman BP, et al. HLA and smoking in prediction and prognosis of small cell lung cancer in autoimmune Lambert-Eaton myasthenic syndrome. J Neuroimmunol 2005; 159: 230-7.
48. Wulff H, Beeton C, Chandy KG. Potassium channels as therapeutic targets for autoimmune disorders. Curr Opin Drug Discov Devel 2003; 6: 640-7
49. + channel expression during B cell differentiation: Implications for immunomodulation and autoimmunity. J Immunol 2004; 173: 776-86.
50. + channel, IKCa1: A potential immunosuppressant. Proc Natl Acad Sci USA 2000; 97: 8151-6.
51. Wulff H, Mullen K, Beeton C, Wang P, Counts D, Calabresi PA, et al. Targeting disease-specific autoreactive T cells with Kv1.3 blockers: A new therapy for autoimmune diseases. Biophys J 2005; 88: 105-Plat.
52. + effector memory cells relative to central memory cells. Blood 2004; 103: 3986-8.
53. Yaniv G, Shilkrut M, Lotan R, Berke G, Larisch S, Binah O. Hypoxia predisposes neonatal rat ventricular myocytes to apoptosis induced by activation of the Fas (CD95/Apo-1) receptor: Fas activation and apoptosis in hypoxic myocytes. Cardiovasc Res 2002; 54: 611-23.
54. Yeromin AV, Zhang SL, Jiang W, Yu Y, Safrina, O, Cahalan MD. Molecular identification of the CRAC channel by altered ion selectivity in a mutant of Orai. Nature 2006; 443: 226-9.
55. Zhang SL, Yu Y, Roos J, Kozak JA, Deerinck TJ, Ellisman MH, et al. STIM1 is a Ca2+ sensor that activates CRAC channels and migrates from the Ca2+ store to the plasma membrane. Nature 2005; 437: 902-5.
56. Zweifach A, Lewis RS. Mitogen-regulated Ca2+ current of T lymphocytes is activated by depletion of intracellular Ca2+ stores. Proc Natl Acad Sci USA 1993; 90: 6295-9.
57. Feske S, Prakriya M, Rao A, Lewis RS. A severe defect in CRAC Ca2+ channel activation and altered K+ channel gating in T cells from immunodeficient patients. J Exp Med 2005; 202: 651-62.
58. Feske S, Gwack Y, Prakriya M, Srikanth S, Puppel SH, Tanasa B, et al. A mutation in Orail causes immune deficiency by abrogating CRAC channel function. Nature 2006; 441: 179-85.
59. Prakriya M, Feske S, Gwack Y, Srikanth S, Rao A, Hogan PG. Orail is an essential pore subunit of the CRAC channel. Nature 2006; 443: 230-3
60. Kotturi MF, Carlow DA, Lee JC, Ziltener HJ, Jefferies WA. Identification and functional characterization of voltage-dependent calcium channels in T lymphocytes. J Biol Chem 2003; 278: 46949-60.
61. Panyi G, Vamosi G, Bodnar A, Gaspar R, Damjanovich S. Looking through ion channels: Recharged concepts in T-cell signaling. Trends Immunol 2004; 25: 565-9.
62. Grissmer S, Nguyen AN, Aiyar J, Hanson DC, Mather RJ, Gutman GA, et al. Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1. 1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. Mol Pharmacol 1994; 45: 1227-34.
63. Cahalan MD, Wulff H, Chandy KG. Molecular properties and physiological roles of ion channels in the immune system. J Clin Immunol 2001; 21:235-52.
64. Panyi G, Varga Z, Gaspar R. Ion channels and lymphocyte activation. Immunol Lett 2004; 92: 55-66.
65. + channels in human T lymphocytes: A role in mitogenesis? Nature 1984; 307: 465-8.
66. Matteson DR, Deutsch C. K channels in T lymphocytes: A patch clamp study using monoclonal antibody adhesion. Nature 1984; 307:468-71.
67. Grissmer S, Nguyen AN, Cahalan MD. Calcium-activated potassium channels in resting and activated human T lymphocytes. Expression levels, calcium dependence, ion selectivity, and pharmacology. J Gen Physiol 1993; 102: 601-30.
68. Krasznai Z. Ion channels in T cells: From molecular pharmacology to therapy. Arch Immunol Ther Exp (Warsz ) 2005; 53: 127-35.
69. Panyi G. Biophysical and pharmacological aspects of K+ channels in T lymphocytes. Eur Biophys J 2005; 34: 515-29.
70. Long SB, Campbell EB, MacKinnon R. Crystal structure of a mammalian voltage-dependent Shaker family K+ channel. Science 2005; 309: 897-903.
71. Cahalan MD, Chandy KG, Decoursey TE, Gupta S. A voltage-gated potassium channel in human T lymphocytes. J Physiol (Lond) 1985; 358: 197-237.
72. Pahapill PA, Schlichter LC. Modulation of potassium channels in intact human T lymphocytes. J Physiol (Lond) 1992; 445: 407-30.
73. Grinstein S, Dixon SJ. Ion transport, membrane potential, and cytoplasmic pH in lymphocytes: Changes during activation. Physiol Rev 1989; 69: 417-81.
74. Lewis RS, Cahalan MD. Potassium and calcium channels in lymphocytes. Annu Rev Immunol 1995; 13: 623-53.
75. Fanger CM, Ghanshani S, Logsdon NJ, Rauer H, Kalman K, Zhou J, et al. Calmodulin mediates calcium-dependent activation of the intermediate conductance KCa charmel, IKCa1. J Biol Chem 1999; 274: 5746-54.
76. + channels as targets for specific immunomodulation. Trends Pharmacol Sci 2004; 25: 280-9.
77. Leonard RJ, Garcia ML, Slaughter RS; Reuben JP. Selective blockers of voltage-gated K+ channels depolarize human T lymphocytes: Mechanism of the antiproliferative effect of charybdotoxin. Proc Natl Acad Sci USA 1992; 89: 10094-8.
78. Lin CS, Boltz RC, Blake JT, Nguyen M, Talento A, Fischer PA, et al. Voltage-gated potassium channels regulate calcium-dependent pathways involved in human T lymphocye activation. J Exp Med 1993; 177: 637-45.
79. Ghanshani S, Wulff H, Miller MJ, Rohm H, Neben A, Gutman GA, et al. Up-regulation of the IKCa1 potassium channel during T-cell activation. Molecular mechanism and functional consequences. J Biol Chem 2000; 275: 37137-49.
80. Fanger CM, Rauer H, Neben AL, Miller MJ, Wulff H, Rosa JC, et al. Calcium-activated potassium channels sustain calcium signaling in T lymphocytes. Selective blockers and manipulated channel expression levels. J Biol Chem 2001; 276: 12249-56.
81. MacLennan IC, Casamayor-Palleja M, Toellner KM, Gulbranson-Judge A, Gordon J. Memory B-cell clones and the diversity of their members. Semin Immunol 1997; 9: 229-34.
82. Carrillo J, Puertas MC, Alba A, Ampudia RM, Pastor X, Planas R, et al. Islet-infiltrating B-cells in nonobese diabetic mice predominantly target nervous system elements. Diabetes 2005; 54: 69-77.
83. O'Connor KC, Bar-Or A, Hafler DA. The neuroimmunology of multiple sclerosis: Possible roles of T and B lymphocytes in immunopathogenesis. J Clin Immunol 2001; 21: 81-92.
84. Kivisakk P, Mahad DJ, Callahan MK, Sikora K, Trebst C, Tucky B, et al. Expression of CCR7 in multiple sclerosis: Implications for CNS immunity. Ann Neurol 2004; 55: 627-38.
85. + channels improves experimental autoimmune encephalomyelitis and inhibits T cell activation. J Immunol 2001; 166: 936-44.
86. + channels ameliorates experimental autoimmune encephalomyetitis, a model for multiple sclerosis. Proc Natl Acad Sci USA 2001; 98: 13942-7.
87. Beeton-C, Pennington MW, Wulff H, Singh S, Nugent D, Crossley G, et al. Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. Mol Pharmacol 2005; 67: 1369-81.
88. Ben Nun A, Cohen IR. Experimental autoimmune encephalomyelitis (EAE) mediated by T cell lines: Process of selection of lines and characterization of the cells. J Immunol 1982; 129: 303-8.
89. Beeton C, Wulff H, Standifer NE, Azam P, Mullen KM, Pennington M. et al. Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc Natl Acad Sci USA 2006; 103: 17414-9.
90. Ezawa K, Yamamura M, Matsui H, Ota Z, Makino H. Comparative analysis of CD. Acta Med Okayama 1997; 51: 25-31.
91. Friedrich M. Krammig S, Henze M, Docke WD, Sterry W, Asadullah K. Flow cytometric characterization of lesional T cells in psoriasis: intracellular cytokine and surface antigen expression indicates an activated, memory/effector type 1 immunophenotype. Arch Dermatol Res 2000; 292: 519-21.
92. Mouhat S, Visan V, Ananthakrishnan S, Wulff H, Andreotti N, Grissmer S, et al. K+ channel types targeted by synthetic OSK1, a toxin from Orthochirus scrobiculosus scorpion venom. Biochem J 2005; 385: 95-104.
93. Kalman K, Pennington MW, Lanigan MD, Nguyen A, Rauer H, Mahnir V, et al. ShK-Dap22, a potent Kv1.3-specific immunosuppressive polypeptide. J Biol Chem 1998; 273: 32697-707.
94. Peter MJ, Varga Z, Hajdu P, Gaspar RJ, Damjanovich S, Horjales E, et al. Effects of toxins Pi2 and Pi3 on human T lymphocyte Kv1.3 channels: The role of Glu7 and Lys24. J Membr Biol 2001; 179: 13-25.
95. Bagdany M, Batista CV, Valdez-Cruz NA, Somodi S, Rodriguez de la Vega RC, Licea AF, et al. Anuroctoxin, a new scorpion toxin of the alpba-KTx 6 subfamily, is highly selective for Kv1.3 over IKCa1 ion channels of human T lymphocytes. Mol Pharmacol 2005; 67: 1034-44.
96. Panyi G, Possani LD, Rodriguez de la Vega RC, Gaspar R, Varga Z. K+ channel blockers: Novel tools to inhibit T cell activation leading to specific immunosuppression. Curr Pharm Des 2006; 12: 2199-220.
97. Dalakas MC. B cells in the pathophysiology of autoimmune neurological disorders: A credible therapeutic target. Pharmacol Ther 2006; 112: 57-70.
98. Lang B, Vincent A. Autoantibodies to ion channels at the neuromuscular junction. Autoimmun Rev 2003; 2: 94-100.
99. Drachman DB. Myasthenia gravis. N Engl J Med 1994; 330: 1797- 810.
100. Kostelidou K, Trakas N, Zouridakis M, Bitzopoulou K, Sotiriadis A, Gavra I, et al. Expression and characterization of soluble forms of the extracellular domains of the beta, gamma and epsilon subunits of the human muscle acetylcholine receptor. FEBS J 2006; 273: 3557-68.
101. Krusek J, Vyskocil F. Different degree of cooperativity in adult, embryonic and mutated mouse muscle nicotinic receptors. Biochim Biophys Acts, 2003; 1646: 119-30.
102. Buckley C, Vincent A. Autoimmune channelopathies. Nat Clin Pract Neurol 2005; 1: 22-33.
103. Baggi F, Annoni A, Ubiali F, Milani M, Longhi It, Scaioli W, et al. Breakdown of tolerance to a self-peptide of acetylcholine receptor alpha-subunit induces experimental myasthenia gravis in rats. J Immunol 2004; 172: 2697-703.
104. Plested CP, Newsom-Davis J, Vincent A. Seronegative myasthenia plasmas and non-IgG fractions transiently inhibit nAChR function. Ann N Y Acad Sci 1998; 841: 501-4.
105. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001; 7: 365-8.
106. Benatar M, Blaes F, Johnston I, Wilson K, Vincent A, Beeson D, et al. Presynaptic neuronal antigens expressed by a small cell lung carcinoma cell line. J Neuroimnumol 2001; 113: 153-62.
107. Catterall WA. Structure and regulation of voltage-gated Ca2+ channels. Annu Rev Cell Dev Biol 2000; 16: 521-55.
108. Hofmann F, Biel M, Flockerzi V. Molecular basis for Ca2+ channel diversity. Annu Rev Neurosci 1994; 17: 399-418.
109. Catterall WA, Perez-Reyes E, Snutch TP, Striessnig J. International Union of Pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels. Pharmacol Rev 2005; 57: 411-25.
110. Mareska M, Gutmann L. Lambert-Eaton myasthenic syndrome. Sémin Neurol 2004; 24: 149-53.
111. Motomura M, Lang B, Johnston I, Palace J, Vincent A, Newsom-Davis J. Incidence of senim anti-P/O-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. J Neurol Sci 1997; 147: 35-42.
112. Chalk CH, Murray NM, Newsom-Davis J, O'Neill JH, Spiro SG. Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma. Neurology 1990; 40: 1552-6.
113. Maddison P, Newsom-Davis J, Mills KR, Souhami RL. Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma. Lancet 1999; 353: 117-8.
114. Liguori R, Vincent A, Clover L, Avoni P, Plazzi G, Cortelli P, et al. Morvan's syndrome: Peripheral and central nervous system and cardiac involvement with antibodies to voltage-gated potassium channels. Brain 2001; 124: 2417-26.
115. Newsom-Davis J, Buckley C, Clover L, Hart I, Maddison P, Tuzum E, et al. Autoimmune disorders of neuronal potassium channels. Ann N Y Acad Sci 2003; 998: 202-10.
116. Pozo-Rosich P, Clover L, Saiz A, Vincent A, Graus F. Voltage-gated potassium channel antibodies in limbic encephalitis. Ann Neurol 2003; 54: 530-3.
117. Arimura K, Sonoda Y, Watanabe O, Nagado T, Kurono A, Tomimitsu H, et al. Isaacs' syndrome as a potassium channelopathy of the nerve. Muscle Nerve 2002; Suppl 11: S55-8.
118. Hart IK, Waters C, Vincent A, Newland C, Beeson D, Pongs O, et al. Autoantibodies detected to expressed K+ channels are implicated in neuromyotonia. Ann Neurol 1997; 41: 238-246.
119. Hille B. Ion channels of excitable membranes. Sunderland, MA Sinauer Associates Inc., 1992
120. Johnston D, Hoffman DA, Magee JC, Poolos NP, Watanabe S, Colbert CM, et al. Dendritic potassium channels in hippocampal pyramidal neurons. J Physiol 2000; 525(Pt 1): 75-81.
121. Dodson PD, Forsythe ID. Presynaptic K+ channels: Electrifying regulators of synaptic terminal excitability. Trends Neurosci 2004; 27: 210-7.
122. Nagado T, Arimura K, Sonoda Y, Kurono A, Horikiri Y, Kameyama A, et al. Potassium current suppression in patients with peripheral nerve hyperexcitability. Brain 1999; 122 ( Pt 11): 2057-66.
123. Kleopa KA, Elman LB, Lang B, Vincent A, Scherer SS. Neuromyotonia and limbic encephalitis sera target mature Shaker-type K+ channels: Subunit specificity correlates with clinical manifestations. Brain 2006; 129: 1570-84.
124. Bien CG, Granata T, Antozzi C, Cross JH, Dulac O, Kurthen M, et al. Pathogenesis, diagnosis and treatment of Rasmussen encephalitis: a European consensus statement. Brain 2005; 128: 454-71.
125. McNamara JO, Whitney KD, Andrews PI, He XP, Janumpalli S, Patel MN. Evidence for glutamate receptor autoimmunity in the pathogenesis of Rasmussen encephalitis. Adv Neurol 1999; 79: 543-50.
126. Freeman JM. Rasmussen's syndrome: Progressive autoimmune multi-focal encephalopathy. Pediatr Neurol 2005; 326 295-9.
127. DeGiorgio LA, Konstantinov KN, Lee SC, Hardin JA, Volpe BT, Diamond B. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat Med 2001; 7: 1189-93.
128. Kowal C, DeGiorgio LA, Nakaoka T, Hetherington H, Huerta PT, Diamond B, et al. Cognition and immunity; antibody impairs memory. Immunity 2004; 21: 179-88.
129. Omdal R, Brokstad K, Waterloo K, Koldingsnes W, Jonsson R, Mellgren SI. Neuropsychiatric disturbances in SLE are associated with antibodies against NMDA receptors. Eur J Neurol 2005; 12: 392-8.
130. Nishio A, Katakai T, Oshima C, Kasakura S, Sakai M, Yonehara S, et al. A possible involvement of Fas-Fas ligand signaling in the pathogenesis of murine autoimmune gastritis. Gastroenterology 1996; 111: 959-67.
131. Chervonsky AV, Wang Y, Wong FS, Visintin I, Flavell RA, Janeway CA Jr, et al. The role of Fas in autoimmune diabetes. Cell 1997; 89: 17-24.
132. Ishiyama. S, Hiroe M, Nishikawa T, Shimojo T, Abe S, Fujisaki H, et al. The Fas/Fas ligand system is involved in the pathogenesis of autoimmune myocarditis in rats. J Immunol 1998; 161: 4695-701.
133. Berke G. The Fas-based mechanism of lymphocytotoxicity. Hum Immunol 1997; 54: 1-7.
134. Binah O. Immune effector mechanisms in myocardial pathologies. Int J Mol Med 2000; 6: 3-16.
135. Bialik S, Geenen DL, Sasson IE, Cheng R, Horner JW, Evans SM, et al. Myocyte apoptosis during acute myocardial infarction in the mouse localizes to hypoxic regions but occurs independently of p153. J Clin Invest 1997; 100: 1363-72.
136. Gulbins E, Szabo I, Baltzer K, Lang F. Ceramide-induced inhibition of T lymphocyte vottage-gated potassium channel is mediated by tyrosine kinases. Proc Natl Acad Sci USA 1997; 94: 7661-6.
137. Detre C, Kiss E, Varga Z, Ludanyi K, Paszty K, Enyedi A, et al. Death or survival: Membrane ceramide controls the fate and activation of antigen-specific T-cells depending on signal strength and duration. Cell Signal 2006; 18: 294-306.
138. Hajdu P, Varga Z, Pieri C, Panyi G, Gaspar R, Jr. Cholesterol modifies the gating of Kv1.3 in human T lymphocytes. Pflugers Arch 2003; 445: 674-82.
139. Cayabyab FS, Khanna R, Jones OT, Schlichter LC. Suppression of the rat microglia Kv1.3 current by src-family tylosine kinases and oxygen/ glucose deprivation. Eur J Neurosci 2000; 12: 1949-60.
140. Hanada T, Lin L, Chandy KG, Oh SS, Chishti AH. Human homologue of the Drosophila discs large tumor suppressor binds to p56lck tyrosine kinase and Shaker type Kv1.3 potassium channel in T lymphocytes. J Biol Chem 1997; 272: 26899-904.
141. Lepple-Wienhues A, Belka C, Laun T, Jekle A, Walter B, Wieland U, et al. Stimulation of CD95 (Fas) blocks T lymphocyte calcium channels through sphingomyelinase and sphingolipids. Proc Natl Acad Sci USA 1999; 96: 13795-800.
142. Lepple-Wienhues A, Szabo I, Laun T, Kaba NK, Gulbins E, Lang F. The tyrosine kinase p56lck mediates activation of swelling-induced chloride channels in lymphocytes. J Cell Biol 1998; 141: 291-6.
143. Dallaporta B, Hirsch T, Susin SA, Zamzami N, Larochette N, Brenner C, et al. Potassium leakage during the apoptotic degradation phase. J Immunol 1998; 160: 5605-15.
144. Kotecha, SA, Schlichter LC. A Kv1.5 to Kv1.3 switch in endogenous hippocampal microglia and a role in proliferation. J Neurosci 1999; 19: 10680-93.
145. Mullen KM, Rozycka M, Rus H, Hu L, Cudrici C, Zafranskaia E, et al. Potassium channels Kv1.3 and Kv1.5 are expressed on blood-derived dendritic cells in the central nervous system. Ann Neurol 2006; 60: 118-27.
146. Panyi G, Bagdany M, Bodnar A, Vamosi G, Szentesi G, Jenei A, et al. Colocalization and nonrandom distribution of Kv1.3 potassium channels and CD3 molecules in the plasma membrane of human T lymphocytes. Proc Natl Acad Sci USA 2003; 100: 2592-7.
147. Panyi G, Vamosi G, Bacso Z, Bagdany M, Bodnar A, Varga Z, et al. Kv1.3 potassium channels are localized in the immunological synapse formed between cytotoxic and target cells. Proc Natl Acad Sci USA 2004; 101: 1285-90.
148. Iruretagoyena, MI, Wiesendanger M, Kalergis AM. The dendritic cell-T cell synapse as a determinant of autoimmune pathogenesis. Curr Phann Des 2006; 12(2): 131-47.
149. Lemieux R, Bazin R. Autoantibody-induced formation of immune complexes in normal human serum. Curr Pharm Des 2006; 12(2): 173-9.
150. Pearl-Yafe M, Kaminitz A, Yolcu ES, Yaniv I, Stein I, Askenasy N. Pancreatic islets under attack: Cellular and molecular effectors. Curr Pharm Des 2007; 13(7): 749-60.